Pan-RAF Inhibitors for Paediatric Low-grade Gliomas Offer New Opportunities in Targeted Therapy

Low-grade gliomas are the most common brain tumour to occur in childhood. The identification of mitogen-activated protein kinase pathway as near-uniform driver these tumours has led testing therapies targeted at this pathway, with promising early results. pan-RAF inhibitor tovorafenib is one recent agents be tested for paediatric low-grade gliomas, data raising prospect that we may dawn a new era management childhood tumour.